Back

SIOP 2020 - 52nd Annual Congress of the International Society of Paediatric Oncology (Virtual Meeting)

Oct 14 - Oct 17, 2020 | OttawaCanada

LARVOL is not affiliated with 52nd Annual Congress of the International Society of Paediatric Oncology (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners

Showing 16 abstracts linked to Trials

[VIRTUAL] PRELIMINARY RESULTS OF THE FIRST PROSPECTIVE MULTI-INSTITUTIONAL TREATMENT STUDY IN CHILDREN WITH B-CELL NON-HODGKIN LYMPHOMA/LEUKEMIA (CCCG-BNHL-2015): A REPORT FROM THE CHINESE CHILDREN’S CANCER GROUP

[VIRTUAL] ACHIEVEMENT OF A MAXIMAL CARDIOPULMONARY EXERCISE TESTING IN CHILDHOOD CANCER SURVIVORS

  • Poster

[VIRTUAL] TREATMENT AND OUTCOME OF CHILDREN WITH WILMS TUMOUR AT MUHIMBILI NATIONAL HOSPITAL, TANZANIA

  • Poster

[VIRTUAL] SURVIVAL OF PEDIATRIC HODGKIN PATIENTS TREATED WITH DOXORUBICIN, BLEOMYCIN, VINCRISTINE, ETOPOSIDE, PREDNISONE AND CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN, BLEOMYCIN, VINCRISTINE, AND DACARBAZINE AT A SINGLE INSTITUTION

  • Poster

[VIRTUAL] FOXO1-FUSIONS (PAX3-FKHR & PAX7-FKHR) IN NON-METASTATIC CHILDHOOD RHABDOMYOSARCOMA (RMS): PREVALENCE, RISK-MIGRATION AND IMPACT ON OUTCOME.

  • Poster

[VIRTUAL] VALUE OF ZOLENDRONIC ACID MAINTENANCE THERAPY IN PATIENTS WITH STANDARD RISK LOCALIZED EWING SARCOMA. REPORT FROM THE INTERNATIONAL EWING 2008 TRIAL.

  • Poster

[VIRTUAL] INTERNATIONAL, MULTICENTER PHASE II TRIAL WITH HUMANIZED ANTI-GD2 MONOCLONAL ANTIBODY NAXITAMAB FOR TREATMENT OF REFRACTORY/RELAPSED HIGH-RISK NEUROBLASTOMA: EFFICACY AND SAFETY DATA

  • Poster

[VIRTUAL] LAROTRECTINIB DEMONSTRATES DURABLE EFFICACY AND SAFETY IN AN EXPANDED DATASET OF PEDIATRIC PATIENTS WITH TRK FUSION CANCER

[VIRTUAL] UPDATED ENTRECTINIB DATA FROM A PHASE 1/2 TRIAL IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

  • Poster

[VIRTUAL] SAFETY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF COBIMETINIB IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSED SOLID TUMOURS: IMATRIX-COBI, A PHASE I/II STUDY

  • Poster

[VIRTUAL] PHASE 1 STUDY OF TAZEMETOSTAT, AN ENHANCER OF ZESTE HOMOLOG-2 (EZH2) INHIBITOR, IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY INTEGRASE INTERACTOR 1 (INI1)-NEGATIVE TUMORS

  • Poster